Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 06.07.2026 2 Am J Gastroenterol 4 Anticancer Res 1 Biochem Biophys Res Commun 14 BMC Cancer 42 BMC Gastroenterol 1 Cancer Res 1 Dig Dis Sci 1 Endoscopy 1 Eur J Pediatr 1 Eur Radiol 1 Gut 1 Int J Cancer 1 J Comput Assist Tomogr 2 J Gastroenterol Hepatol 1 J Hepatol 1 Oncogene 2 PLoS One 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. XU Y, Yao X, Wang Y, Zhao Q, et al
   Refined Carbohydrate, Different Staple Foods Intake and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Community-Based Cohort Study.
   Am J Gastroenterol. 2026;121:1619-1629.
   PubMed         Abstract available
   
   
2. AMJAD W, Thuluvath PJ
   Budd-Chiari Syndrome: Presentation, Management, and Prognosis.
   Am J Gastroenterol. 2026;121:1562-1575.
   PubMed         Abstract available
   
   

   
   Anticancer Res

3. KUWANO A, Yada M, Tanaka K, Hamamoto T, et al
   Pretreatment Tumor-infiltrating CD8(+) T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma.
   Anticancer Res. 2026;46:4077-4085.
   PubMed         Abstract available
   
   
4. NAKAMURA D, Motoyoshi Y, Nagaoka S, Komori A, et al
   Complementary Prognostic Value of ALBI Grade and Child-Pugh Classification in HCC Treated With SBRT.
   Anticancer Res. 2026;46:3955-3965.
   PubMed         Abstract available
   
   
5. ONO A, Masuda T, Okabe H, Tomita M, et al
   Rapidly Progressive Multiple Hepatic Hemangiomas Mimicking Angiosarcoma: A Case Report With Surgical and Interventional Management.
   Anticancer Res. 2026;46:4161-4167.
   PubMed         Abstract available
   
   
6. HASEGAWA N, Hoshiai S, Yamada T, Takahashi N, et al
   Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab.
   Anticancer Res. 2026;46:3897-3906.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

7. ZHUANG W, Xiao G, Zhang M, Wang J, et al
   GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma.
   Biochem Biophys Res Commun. 2026;829:154190.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. WANG Y, Lu M, Su X, Cui C, et al
   Trend analysis of liver cancer mortality in Chinese residents from 2002 to 2021.
   BMC Cancer. 2026;26:337.
   PubMed         Abstract available
   
   
9. ZHANG W, Wu X, Sun X, Wen J, et al
   Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.
   BMC Cancer. 2026 Jan 23. doi: 10.1186/s12885-026-15616.
   PubMed        
   
   
10. ZHU H, Cai Y, Ke C, Wang H, et al
    Clinical risk factors and survival analysis of postoperative recurrence or metastasis of colorectal cancer.
    BMC Cancer. 2026 Feb 24. doi: 10.1186/s12885-026-15779.
    PubMed         Abstract available
    
    
11. SAHM SW, Neumann UP, Zahn MO, Schwittay M, et al
    ERBITAG: Non-interventional study on the efficacy of cetuximab in first-line therapy in patients with RAS wild-type metastatic colorectal cancer.
    BMC Cancer. 2026 Feb 25. doi: 10.1186/s12885-026-15753.
    PubMed        
    
    
12. ASBAGHI O, Shimi G, Ghorbani A, Zand H, et al
    A systematic review and meta-analysis examining the relationship between hyperthyroidism or hypothyroidism and the probability of developing liver cancer.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15405.
    PubMed         Abstract available
    
    
13. HOU S, Wu X, Zhu H, Yao Y, et al
    The prognostic value of immunoscore in colorectal cancer liver metastases: a meta-analysis reveals the superiority of metastatic over primary tumor profiling.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15867.
    PubMed        
    
    
14. KO YG, Lee SY, Lee WK, Park JH, et al
    Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model.
    BMC Cancer. 2025;26:61.
    PubMed         Abstract available
    
    
15. PENG SL, Zhou YL, Liang X, Jiang RW, et al
    CS2164 combined with radiation suppressed tumor growth via gamma-H2AX persistence and ROS accumulation.
    BMC Cancer. 2026;26:526.
    PubMed         Abstract available
    
    
16. GIEHL-BROWN E, Nikbakhsh R, Mansourkiaei A, Jotten L, et al
    Delaying surgery beyond six weeks after systemic therapy reduces postoperative morbidity without evidence of impaired oncologic outcomes in colorectal liver metastases.
    BMC Cancer. 2026;26:786.
    PubMed         Abstract available
    
    
17. FRIEDMAN LR, Smith EC, Sarvestani AL, Eade AV, et al
    Study protocol: targeted delivery of interleukin-12 in combination with hepatic artery infusion pump therapy for patients with adrenocortical carcinoma liver metastases.
    BMC Cancer. 2026 Jun 27. doi: 10.1186/s12885-026-16425.
    PubMed         Abstract available
    
    
18. TENG H, Qin N, Liu K, Gong C, et al
    Efficacy and safety of albumin-bound paclitaxel combined with anlotinib and immunotherapy in advanced non-small cell lung cancer with liver metastases: a retrospective study.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15996.
    PubMed        
    
    
19. HASHINOKUCHI H, Yamakuchi M, Higashi S, Takenouchi K, et al
    AMPK/p38 MAPK signaling selectively enhances HIF-induced VEGF-A165 expression under hypoxic and low-glucose conditions in HepG2 cells to promote endothelial cell proliferation and migration.
    BMC Cancer. 2026;26:782.
    PubMed         Abstract available
    
    
20. THANG SS, Muralidharan V, Spanger M, Page P, et al
    A retrospective analysis of Selective Internal Radiation Therapy (SIRT) and chemotherapy for metastatic pancreatic adenocarcinoma.
    BMC Cancer. 2026;26:790.
    PubMed         Abstract available
    
    
21. SUN J, Fang J, Shan Y, Yu X, et al
    The predictive value of the lymphocyte-C-reactive protein ratio for early recurrence in MVI positive HCC patients who underwent postoperative adjuvant transcatheter arterial chemoembolization.
    BMC Cancer. 2026;26:672.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

22. ZHOU T, Zhou Y, Comert C, Zhou XY, et al
    Energy metabolism alteration and gene expression reprogramming in a cell model of high fat load non-alcoholic fatty liver disease.
    BMC Gastroenterol. 2026;26:160.
    PubMed         Abstract available
    
    
23. NAREM RSR, Mathakala V, Sallabathula ST, Peddiboyina VL, et al
    Probiotics as emerging adjuncts in metabolic associated fatty liver disease therapy-a systemic review.
    BMC Gastroenterol. 2026;26:156.
    PubMed         Abstract available
    
    
24. ZHENG Z, Yang M, Ma L, Ma J, et al
    Transjugular liver biopsy in patients with unexplained liver dysfunction and bleeding tendency: a safety and efficacy analysis.
    BMC Gastroenterol. 2026;26:146.
    PubMed         Abstract available
    
    
25. XIE Y, Li H, Xu Y, Lv D, et al
    Association between remnant cholesterol and cardiometabolic multimorbidity in non-alcoholic fatty liver disease patients: evidence from a cross-sectional study.
    BMC Gastroenterol. 2026;26:142.
    PubMed         Abstract available
    
    
26. SWANN R, Lewsey J, Jamieson D, Padmanabhan S, et al
    Identifying patients at high risk of decompensated liver disease through unscheduled care attendance data: a retrospective cohort study.
    BMC Gastroenterol. 2026;26:126.
    PubMed         Abstract available
    
    
27. ZHANG H, Guo M, Liang X, Wan D, et al
    Comparison of diagnostic value of abdominal obesity and metabolism-related indicators for non-alcoholic fatty liver disease in lean individuals.
    BMC Gastroenterol. 2026;26:111.
    PubMed         Abstract available
    
    
28. HAN Z, Ran Y, Liu R, Dong S, et al
    FCRL3 as a potential link between Benzo[a]pyrene exposure and primary biliary cholangitis: insights from comparative toxicogenomics and multi-omics analysis.
    BMC Gastroenterol. 2026 Jan 12. doi: 10.1186/s12876-026-04614.
    PubMed        
    
    
29. ROGALSKI J, Grzelczyk J, Margulska A, Mirocha G, et al
    I-FABP, citrulline and non-invasive liver dysfunction indices in patients with depression - cross-sectional study results.
    BMC Gastroenterol. 2026;26:88.
    PubMed         Abstract available
    
    
30. ZHOU X, Gao Z, Ma H, Hu J, et al
    ChatGPT improves usability, effectiveness, scalability, interpretability and accessibility, in early diagnosis of metabolic dysfunction-associated fatty liver disease.
    BMC Gastroenterol. 2025;25:868.
    PubMed         Abstract available
    
    
31. MAO Z, Qian H, Liu R, Huo R, et al
    The relationship between resilience, financial toxicity, and quality of life in patients with primary liver cancer: a cross-sectional study.
    BMC Gastroenterol. 2025;26:32.
    PubMed         Abstract available
    
    
32. SISTANIZAD M, Taherpour N, Alibeigi P, Sadeghi S, et al
    Impact of bariatric surgery on metabolic-dysfunction associated fatty liver disease in diabetic and non-diabetic patients: a cohort study.
    BMC Gastroenterol. 2025;26:18.
    PubMed         Abstract available
    
    
33. XU X, Jiang M, Fu Y, Meng Q, et al
    The effect of TIPS on the development of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.
    BMC Gastroenterol. 2026 Jun 29. doi: 10.1186/s12876-026-05027.
    PubMed         Abstract available
    
    
34. KATTAN SW, Almars AI, Tounsi WA, Turkistani AA, et al
    Silymarin-loaded phytosomal nanoparticles mitigate dyslipidemia, oxidative damage, and hepatic injury in high-fat diet-induced metabolic dysfunction-associated steatotic liver disease in rats.
    BMC Gastroenterol. 2026 Jun 29. doi: 10.1186/s12876-026-05004.
    PubMed         Abstract available
    
    
35. YANG Y, Zeng C, Jin Z, Huang Y, et al
    Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease.
    BMC Gastroenterol. 2025;25:537.
    PubMed         Abstract available
    
    
36. BABAJANI N, Saeedian B, Shirmard FO, Pourfaraji SM, et al
    Diagnostic accuracy of circulating long noncoding RNAs in hepatocellular carcinoma: a systematic review and meta-analysis.
    BMC Gastroenterol. 2026 Jun 30. doi: 10.1186/s12876-026-05049.
    PubMed         Abstract available
    
    
37. TANG N, Guan P, Yang D, Zhang L, et al
    Early prediction of response to chemotherapy with Cetuximab in colorectal liver metastasis with contrast-enhanced ultrasound perfusion analysis.
    BMC Gastroenterol. 2026;26:398.
    PubMed         Abstract available
    
    
38. SHAO J, Zhou L, Wang H, Gu X, et al
    Plasma YAP1 as a biomarker for the prediction of occurrence, progression, and outcomes of sepsis-associated liver injury: a prospective observational study.
    BMC Gastroenterol. 2026;26:393.
    PubMed         Abstract available
    
    
39. WU Y, Wang J, Xing Y, Kang M, et al
    Personalized assessment of hyperuricemia probability in metabolic dysfunction-associated steatotic liver disease: construction and multicenter validation of a clinical nomogram.
    BMC Gastroenterol. 2026;26:405.
    PubMed         Abstract available
    
    
40. ROY A, Jajodia S, Chakraborty S, Keyal S, et al
    Blood-based non-invasive tests show comparable accuracy in MetALD and MASLD for MRE-defined advanced fibrosis.
    BMC Gastroenterol. 2026;26:329.
    PubMed         Abstract available
    
    
41. HUANG X, Wu D, Tang Z, Xu L, et al
    The association of the combined triglyceride-glucose and frailty index with chronic liver disease: evidence from the CHARLS study.
    BMC Gastroenterol. 2026;26:317.
    PubMed         Abstract available
    
    
42. FTEAH AM, Aly DM, Elrefaiy MA, Rahim AA, et al
    GCKR genetic variants and circulating FGF21 identify a metabolic risk signature in metabolic dysfunction-associated steatotic liver disease.
    BMC Gastroenterol. 2026;26:230.
    PubMed         Abstract available
    
    
43. SHIN J, Heo SJ, Lee YJ, Kwon YJ, et al
    Associations of body roundness index with steatotic liver disease and mortality from the UK biobank cohort study.
    BMC Gastroenterol. 2026;26:312.
    PubMed         Abstract available
    
    
44. YANG J, Li X, Qi F
    Association of metabolic syndrome and its severity with liver fibrosis: a cross-sectional study based on NHANES 2017-March 2020, 2021-2023.
    BMC Gastroenterol. 2026;26:296.
    PubMed         Abstract available
    
    
45. ALANAZI MA, Alshahrani SA, Elkarouri A, Alkholaifi SA, et al
    Demographic profiles and disparities in all liver diseases and diabetes mellitus patients - related mortality among older adults (>/= 65) in the United States, 1999 to 2020.
    BMC Gastroenterol. 2026;26:287.
    PubMed         Abstract available
    
    
46. WANG F, Liu M, Liang M, Zhang D, et al
    Interpretable stacking model integrating intra-/peritumoral CT-radiomics and serum biomarkers for predicting microvascular invasion in HCC: a dual-center retrospective study.
    BMC Gastroenterol. 2026;26:275.
    PubMed         Abstract available
    
    
47. JU R, Tian S, Li B, Zhang M, et al
    Extracellular vesicles derived from live or apoptotic mesenchymal stem cells: comparison of the effects of two extracellular vesicles on liver fibrosis.
    BMC Gastroenterol. 2026;26:265.
    PubMed         Abstract available
    
    
48. MAHMOUD HA, Abd Elghany WM, Abdelhakeem M, Ahmed HM, et al
    Association between serum uric acid and non-alcoholic fatty liver disease (NAFLD): an observational cross-sectional study in an Egyptian outpatient cohort.
    BMC Gastroenterol. 2026;26:177.
    PubMed         Abstract available
    
    
49. LIU L, Chen D, Wang S, Si W, et al
    Nonlinear associations of remnant cholesterol/high-density lipoprotein cholesterol ratio with the risk of metabolic-associated fatty liver disease: a cross-sectional study.
    BMC Gastroenterol. 2026;26:248.
    PubMed         Abstract available
    
    
50. LIN H, Wang Z, Tang J, Liu X, et al
    Metabolic characteristics and risk profile of non-obese fatty liver disease in an elderly Chinese community cohort.
    BMC Gastroenterol. 2026;26:244.
    PubMed         Abstract available
    
    
51. KAWAS H, Alabbas M, Abu-Hammour MN, Eren B, et al
    High-intensity hydrophilic versus lipophilic statins in patients with primary biliary cholangitis: a multi-institutional analysis.
    BMC Gastroenterol. 2026 Mar 10. doi: 10.1186/s12876-026-04723.
    PubMed        
    
    
52. WANG Z, Wang Z, Han S, Wang E, et al
    Correlation between liver fat fraction measured by MRI IDEAL-IQ sequence and ALT, GGT, and AST in colorectal cancer patients after chemotherapy.
    BMC Gastroenterol. 2026 Mar 9. doi: 10.1186/s12876-026-04690.
    PubMed        
    
    
53. XIAO J, Tian S, Wu J, Xu Z, et al
    The relationship between metabolic associated fatty liver disease and thyroid nodule: a cross-sectional study in China.
    BMC Gastroenterol. 2026;26:233.
    PubMed         Abstract available
    
    
54. HUANG D, Ma X, Gao Q, Shen X, et al
    Development of a liver stiffness measurement-based nomogram model to identify early CKD risk in patients with MAFLD.
    BMC Gastroenterol. 2026;26:164.
    PubMed         Abstract available
    
    
55. ARAI J, Fujiwara H, Aoki T, Niikura R, et al
    Metabolic factors associated with colorectal neoplasms: a single center retrospective cross-sectional analysis of colonoscopy patients.
    BMC Gastroenterol. 2026;26:225.
    PubMed         Abstract available
    
    
56. HUANG S, Tao J, Xiao H, Wu S, et al
    alpha-AMA induced liver failure is associated with elevation of HMGB1 lactylation modification in mice.
    BMC Gastroenterol. 2026;26:221.
    PubMed         Abstract available
    
    
57. CHEN JN, Delibasi BT, Wang J, Tran T, et al
    Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease.
    BMC Gastroenterol. 2026;26:198.
    PubMed         Abstract available
    
    
58. ALGOBASHY YA, Shehatta AS, Wahab M, Youssef MM, et al
    Leptin, vitamin D, and APRI values during the six months post-liver transplantation.
    BMC Gastroenterol. 2026;26:145.
    PubMed         Abstract available
    
    
59. SUN Z, Wang Y, Tan Z, Zhou J, et al
    Prognostic outcomes of surgery vs. non-surgery in initially unresectable HCC with successful conversion via ICI + TKI therapy.
    BMC Gastroenterol. 2026;26:182.
    PubMed         Abstract available
    
    
60. ZHONG H, Zheng M, Zhao C, Wei Q, et al
    Primary biliary cholangitis with inflammation involving zone 3 of the liver has a poor response to ursodeoxycholic acid treatment: a retrospective cohort study.
    BMC Gastroenterol. 2026 Feb 13. doi: 10.1186/s12876-026-04665.
    PubMed        
    
    
61. CHEN S, Li B, Li S, Lv T, et al
    Direct bilirubin was superior to total bilirubin in predicting the long-term outcomes of patients with primary biliary cholangitis.
    BMC Gastroenterol. 2026 Feb 11. doi: 10.1186/s12876-026-04667.
    PubMed        
    
    
62. ZHU X, Wang Z, Yang X, Ning Z, et al
    Diagnostic performance of TyG-related indices for MAFLD screening in older adults at moderate altitude: TyG-BMI showed the highest discriminatory ability.
    BMC Gastroenterol. 2026;26:172.
    PubMed         Abstract available
    
    
63. AYDAGNUHM GB, Tefera AS, Getahun GT, Melaku EE, et al
    Predictive factors of metabolic dysfunction associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors, multicenter cross-sectional study, North East Ethiopia.
    BMC Gastroenterol. 2026;26:161.
    PubMed         Abstract available
    
    

    
    Cancer Res

64. QIU W, Zeng Y, Fan Z, Su Y, et al
    An SLCO2B1 mRNA Isoform Acts as a Noncoding RNA to Drive Cancer Progression by Triggering Protein Biosynthesis.
    Cancer Res. 2026;86:3142-3159.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

65. BHUVA M, Thompson E, Watson CM, Sava F, et al
    Genetic Analysis of Isolated Hepatic Ductal Plate Malformation Reveals Novel Variants and Insights into Phenotypic Correlation.
    Dig Dis Sci. 2026 Jun 28. doi: 10.1007/s10620-026-10072.
    PubMed         Abstract available
    
    

    
    Endoscopy

66. IWAI T, Tsukamoto M, Ozaki Y, Nishimura M, et al
    Endoscopic retrieval of a migrated plastic stent after endoscopic ultrasound-guided hepaticojejunostomy.
    Endoscopy. 2026 Jun 30. doi: 10.1055/a-2888-0530.
    PubMed        
    
    

    
    Eur J Pediatr

67. VAROL FI, Gungor S, Ekici C, Tekedereli I, et al
    Alagille syndrome case series: five new variants and two large deletions.
    Eur J Pediatr. 2026;185:542.
    PubMed         Abstract available
    
    

    
    Eur Radiol

68. SANDRASEGARAN K, Shah AS, Thompson CP, Jayasekara CR, et al
    Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)?
    Eur Radiol. 2026 Jun 27. doi: 10.1007/s00330-026-12710.
    PubMed         Abstract available
    
    

    
    Gut

69. XIANG YJ, Liu ZH, Feng JK, Qin YY, et al
    Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.
    Gut. 2026 Jul 3:gutjnl-2026-338462. doi: 10.1136/gutjnl-2026-338462.
    PubMed         Abstract available
    
    

    
    Int J Cancer

70. HE D, Zeng X, Yin L, Liu Y, et al
    Sex Hormone Receptors, HBV Integrations and Their Prognostic Predictive Value Among Hepatocellular Carcinoma Patients.
    Int J Cancer. 2026 Jul 3. doi: 10.1002/ijc.70633.
    PubMed         Abstract available
    
    

    
    J Comput Assist Tomogr

71. ZHANG N, Sun H, Ge M, Zhou P, et al
    Evaluation of Gd-EOB-DTPA MRI With Diffusion and Clinicopathologic Features for Predicting Microvascular Invasion in Hepatocellular Carcinoma.
    J Comput Assist Tomogr. 2026 Jul 1. doi: 10.1097/RCT.0000000000001903.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

72. OKUWAKI K, Watanabe M, Uojima H, Hidaka H, et al
    Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens.
    J Gastroenterol Hepatol. 2026;41:2130-2137.
    PubMed         Abstract available
    
    
73. ZENG C, Jiang H, Zhong Y, Wan L, et al
    Toward the Era of Precision Immunotherapy: The Clinical Landscape and Future Directions of mRNA Vaccines for the Treatment of Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2026 Jun 30. doi: 10.1111/jgh.70540.
    PubMed        
    
    

    
    J Hepatol

74. CHEN R, Li J, Zhong X, Wang X, et al
    Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44(+)pDC crosstalk.
    J Hepatol. 2026 Jul 1:S0168-8278(26)02680-2. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    

    
    Oncogene

75. LANG Q, Yin Z, Sun J, Wang Y, et al
    Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.
    Oncogene. 2026 Jul 2. doi: 10.1038/s41388-026-03874.
    PubMed         Abstract available
    
    

    
    PLoS One

76. KHALYFA A, Tu BH, Shi Q, Tanaka T, et al
    Cirrhosis outcomes on rurality and weekend admissions revisited: A contemporary analysis of the national inpatient sample.
    PLoS One. 2026;21:e0353178.
    PubMed         Abstract available
    
    
77. ZHAO Y, Li J, Li X, Zhang M, et al
    Effects of mindfulness-based stress reduction on perioperative outcomes in patients with advanced hepatocellular carcinoma undergoing transarterial chemoembolization.
    PLoS One. 2026;21:e0352434.
    PubMed         Abstract available
    
    

    
    Radiology

78. LI J, Pang C, Li H, Liu G, et al
    Sequencing Ablation and Systemic Therapy in Colorectal Liver Oligometastases: An Upfront versus Delayed Approach Nationwide Analysis.
    Radiology. 2026;319:e251003.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum